What this market covers
Augmentation therapies and supportive care for a genetic condition that damages the lungs and liver. Buyers are hospitals, lung specialists and specialty pharmacies.
Typical segments
- Plasma derived augmentation
- Recombinant therapies
- Gene therapies
- Oxygen and lung care
Why this market is moving now
- US employment in the core industry shifted +23% since 2020.
- Clinical research is active, with studies recruiting now.
Key figures
Each figure names the source it came from. Open the source list below to read the quoted line.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023. | 3,116 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023. | 428.65 EUR billion | 2023 | Eurostat |
| NACE class C2120 employed 600,730 people across the EU in 2023. | 600,730 persons employed | 2023 | Eurostat |
| The US had 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing) in 2025. | 830 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 325414 employed an average of 46,853 people in US private industry in 2025. | 46,853 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 325414 changed by +23% between 2020 (38,064 jobs) and 2025, calculated from BLS figures. | +23 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 325414 was $124,162 in 2025. | 124,162 USD per year | 2025 | U.S. Bureau of Labor Statistics |
| ClinicalTrials.gov lists 147 registered studies for the condition "alpha 1-antitrypsin deficiency". | 147 registered studies | 2026 | U.S. National Library of Medicine |
| 21 of those studies were recruiting participants when checked in November 2026. | 21 recruiting studies | 2026 | U.S. National Library of Medicine |
| PubMed indexed 164 papers mentioning "alpha-1 antitrypsin deficiency" in the title or abstract in 2025. | 164 papers | 2025 | U.S. National Library of Medicine |
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
Quoted lines
- Figure 1
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
- Figure 2
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
- Figure 3
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
- Figure 1
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
Quoted lines
- Figure 4
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_estabs 830
- Figure 5
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_emplvl 46853
- Figure 6
QCEW 2020 annual_avg_emplvl 38064; 2025 annual_avg_emplvl 46853
- Figure 7
QCEW 2025 annual, US000, private, NAICS 325414, avg_annual_pay 124162
- Figure 4
- U.S. National Library of Medicine: ClinicalTrials.gov API v2, condition "alpha 1-antitrypsin deficiency" (2026-11-04)
Quoted lines
- Figure 8
query.cond=alpha 1-antitrypsin deficiency totalCount 147
- Figure 8
- U.S. National Library of Medicine: ClinicalTrials.gov API v2, condition "alpha 1-antitrypsin deficiency", status recruiting (2026-11-04)
Quoted lines
- Figure 9
filter.overallStatus=RECRUITING totalCount 21
- Figure 9
- U.S. National Library of Medicine: PubMed search "alpha-1 antitrypsin deficiency"[tiab] AND 2025[dp] (2026-11-04)
Quoted lines
- Figure 10
esearch count 164
- Figure 10
Buyers and suppliers
Who buys
- Hospitals
- Lung specialists
- Specialty pharmacies
What the full report covers
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the United States market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How many clinical trials study alpha 1-antitrypsin deficiency?
ClinicalTrials.gov lists 147 registered studies.
How many US companies are in the alpha-1 antitrypsin deficiency industry?
BLS counts 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing), the closest official industry.
How many EU companies are in the alpha-1 antitrypsin deficiency industry?
Eurostat counts 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations).
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline